⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL361653 | 0.96 | — | — | |
| SCHEMBL23562129 | 0.86 | APLNR (0.35) | — | |
| SCHEMBL2047407 | 0.86 | APLNR (0.35) | — | |
| Hydrochloric Acid SCHEMBL30062078 | 0.83 | APLNR (0.33) | — | |
| SCHEMBL2047944 | 0.77 | — | — | |
| SCHEMBL1988815 | 0.77 | — | — | |
| SCHEMBL1988817 | 0.77 | — | — | |
| SCHEMBL12238263 | 0.74 | — | — | |
| SCHEMBL22990185 | 0.74 | — | — | |
| SCHEMBL1583919 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1037 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11806346-B2 | HTT modulators for treating Huntington's disease | CHDI FOUNDATION, INC. (US) | 2023-11-07 | — | — | US | claimed |
| EP-4149937-A1 | HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE | CHDI Foundation, Inc. (US) | 2023-03-22 | — | — | EP | claimed |
| US-20220409615-A1 | HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE | CHDI FOUNDATION, INC. | 2022-12-29 | — | — | US | claimed |
| WO-2021231571-A1 | HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE | CHDI FOUNDATION, INC. (US) | 2021-11-18 | — | — | WO | claimed |
| WO-2021079380-A1 | IMPROVED PROCESS FOR THE PREPARATION OF (2S)-N-{(1S)-1-(2-CHLOROPHENYL)-2-[(3,3-DIFLUOROCYCLOBUTYL)-AMINO]-2-OXOETHYL}-1-(4-CYANOPYRIDIN-2-YL)-N-(5-FLUOROPYRIDIN-3-YL)-5-OXOPYRROLIDINE-2-CARBOXAMIDE | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2021-04-29 | — | — | WO | claimed |
| US-10155770-B2 | Substituted pyrazolopyrimidines and method of use | ABBVIE INC. (US) | 2018-12-18 | — | — | US | claimed |
| EP-2867227-B1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2018-11-21 | — | — | EP | claimed |
| EP-3286192-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AND METHOD OF USE | AbbVie Deutschland GmbH & Co KG (DE) | 2018-02-28 | — | — | EP | claimed |
| US-9828381-B2 | Substituted pyrazolopyrimidines and method of use | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-11-28 | — | — | US | claimed |
| US-9487483-B2 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2016-11-08 | — | — | US | claimed |
| WO-2016169995-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AND METHOD OF USE | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-10-27 | — | — | WO | claimed |
| US-20160304527-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AND METHOD OF USE | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-10-20 | — | — | US | claimed |
| US-9394297-B2 | Amides as pim inhibitors | AMGEN INC. (US) | 2016-07-19 | — | — | US | claimed |
| US-20150329538-A1 | AMIDES AS PIM INHIBITORS | AMGEN INC. (US) | 2015-11-19 | — | — | US | claimed |
| US-20150148349-A1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2015-05-28 | — | — | US | claimed |
| EP-2867227-A2 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | Novartis AG (CH) | 2015-05-06 | — | — | EP | claimed |
| WO-2014002058-A2 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2014-01-03 | — | — | WO | claimed |
| EP-2103598-A1 | Fluorinated cycloalkyl-derived benzoylguanidine, method for producing same, use of same as medicine and medicine containing same | Sanofi-Aventis Deutschland GmbH (DE) | 2009-09-23 | — | — | EP | claimed |
| WO-2026107328-A1 | AGONISTS OF PARATHYROID HORMONE 1 AND INCRETIN RECEPTORS | SEPTERNA, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| WO-2003106410-A1 | FLUORINATED CYCLOALKYL-DERIVATISED BENZOYLGUANIDINES AND THEIR USE AS A MEDICAMENT | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-12-24 | — | — | WO | disclosed |